Dr. Lev Goldfarb: the grim life of a Russian "refusenik".
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to C Gray.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
The effect of chronic administration of bromocriptine to 20 patients with the polycystic ovary syndrome (PCOS) was studied. All patients had normal serum prolactin levels. Bromocriptine 7.5 mg daily was administered for up to 1 year and the biochemical and clinical responses assessed at 3-monthly intervals. Over a period of 3 to 12 months significant reductions in serum LH levels, LH/FSH ratios and in plasma testosterone were observed. In 14 patients, blunting of the previously enhanced LH response to LHRH was observed. Clinical improvement also occurred, most notably in menstrual function. In 12 out of 20 patients a monthly cycle was established and in a further three there was an increase in the frequency of menstruation towards normal. Eleven out of 20 patients ultimately noted a subjective improvement in hirsutism. We conclude that bromocriptine, given to patients with polycystic ovarian disease, inhibits LH hypersecretion, leading to restoration of cyclic ovarian function and reduced androgen synthesis.
A prospective study was undertaken to assess the incidence of urethral stricture in 105 men undergoing coronary artery by-pass grafting. A pre-operative urological history was taken and peak urine flow rates measured before surgery, and 1 week and between 6 and 8 weeks after operation. All patients were catheterised in theatre with a standard type and size of urethral catheter and details recorded of the by-pass time and the degree of hypothermia. Postoperative urological problems such as urethral discharge and haematuria were noted. In addition, 100 patients completed a postal questionnaire about urinary symptoms between 4 and 12 months after surgery. The overall incidence of urethral stricture was 2%.
An immunoperoxidase technique has been used to localise clotting factor XIII subunits A and S in human tissues. The presence of factor XIII in placenta and megakaryocytes was confirmed. Factor XIII was also found in fibroblasts, a hitherto unreported finding. Factor XIII subunits were not detected in hepatocytes, although factor XIII was found in fibroblasts in portal tracts. These findings suggest that factor XIII is not synthesised in the liver as previously thought.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.